The Fiscal Challenge of Emerging Gene Therapies | OAS Episode 118
A new category of gene therapies is offering life-changing treatments to people with some forms of cancer and other rare disorders. These revolutionary treatments, however, come with a large price tag, sometimes exceeding millions of dollars for a single patient. Often, these costs fall on state Medicaid systems. On this podcast we discuss how states are dealing with this challenge. One of our guests is Anne Winter, a Medicaid strategist with the national research and consulting firm Health Management Associates. Winter, who has particular expertise in pharmacy benefit management, discusses some of the strategies state are employing. Our other guest is Colleen Becker, a policy expert at NCSL, who lays out the scope of the challenge facing states. Additional Resources NCSL Health Program OAS Episode 118 Transcription
Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A new category of gene therapies is offering life-changing treatments to people with some forms of cancer and other rare disorders. These revolutionary treatments, however, come with a large price tag, sometimes exceeding millions of dollars for a single patient. Often, these costs fall on state Medicaid systems.
On this podcast we discuss how states are dealing with this challenge. One of our guests is Anne Winter, a Medicaid strategist with the national research and consulting firm Health Management Associates. Winter, who has particular expertise in pharmacy benefit management, discusses some of the strategies state are employing.
Our other guest is Colleen Becker, a policy expert at NCSL, who lays out the scope of the challenge facing states.
